Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
CTD_human |
Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis.
|
19020767 |
2008 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
CTD_human |
To test the hypothesis that polymorphisms of the TYMS gene are associated with risk of breast cancer, we genotyped these two polymorphisms in a case-control study of 432 incident cases with invasive breast cancer and 473 cancer-free controls in a Chinese population.
|
16723031 |
2006 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
CTD_human |
Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization.
|
21501481 |
2011 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
CTD_human |
Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
|
19105824 |
2008 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
CTD_human |
In both gastric and colon cancers, thymidylate synthase and orotate phosphoribosyltransferase mRNA expressions were higher (p < 0.0001, p <0.0001 respectively in gastric cancer and P = 0.0002, p < 0.0001 respectively in colon cancer) and dihydropyrimidine dehydrogenase mRNA expressions were lower in cancer cells than in cancerous stroma (P = 0.0136 in gastric cancer and p < 0.0001 in colon cancer).
|
18652704 |
2008 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
CTD_human |
Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential.
|
16609021 |
2006 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
CTD_human |
'High-expression' variants of TS 2R/3R repeat, TS enhancer region 3R G/C, TS 1494del6 bp, and TS haplotype analysis might help to identify stage II and stage III colon cancer patients who are at great risk of developing tumor recurrence, and also those who are more likely to benefit from 5-fluorouracil-based adjuvant chemotherapy.
|
18192902 |
2008 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
CTD_human |
Genotypes resulting in reduced MTHFR activity in conjunction with low TS expression were associated with a reduced risk of colon cancer.
|
16284371 |
2005 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
CTD_human |
TYMS and PGK1, as well as their epitope peptides, might be appropriate target molecules for specific immunotherapy of HLA-A2(+) colon cancer patients because of the positive role of TYMS and PGK1 in chemoresistance (5-fluorouracil) and angiogenesis of tumor cells, respectively.
|
15355913 |
2004 |
Rectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.
|
16931962 |
2006 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
In 140 patients with primary squamous cell carcinoma (SCC) of the tongue, intratumoural TS expression was evaluated by immunohistochemistry.
|
16280240 |
2006 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
|
16943523 |
2006 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Highly Expressed Genes in Rapidly Proliferating Tumor Cells as New Targets for Colorectal Cancer Treatment.
|
25944804 |
2015 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis.
|
19020767 |
2008 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
A VNTR polymorphism in the TS promoter region is associated with the efficacy of 5-FU-based chemotherapy in colorectal cancer.
|
15386371 |
2004 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Moreover, the correlation between TS, DPD and TP expression and cytotoxicity of 5-fluorouracil was evaluated in Colo 320, HT-29, CaCo-2 and SW620 human CRC cell lines.
|
17047489 |
2006 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
This study aimed to assess the range of gene copies per nucleus of thymidylate synthase (TYMS), thymidine phosphorylase (TP) and dihydrofolate reductase (DHFR) in colorectal cancer, and to evaluate its prognostic significance following adjuvant chemotherapy, since these enzymes are closely related to efficacy of 5-fluorouracil (5FU).
|
18607850 |
2008 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
The expression of TS is one of the important prognosis indicators of colorectal carcinoma.
|
15500737 |
2004 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.
|
18676755 |
2008 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
We found that a combination of germline TS polymorphisms is an independent prognostic marker in selecting CRC patients with worse prognosis, and it may be worthwhile to examine whether these patients would benefit from an alternative therapy.
|
16141798 |
2005 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Tumour samples from 73 patients CRC who were treated in advanced stage with either irinotecan alone or in combination with 5-FU/leucovorin, were analysed for expression of TS, hMLH1 and hMSH2 using immunohistochemistry (IHC).
|
17943475 |
2008 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
In this study, TS and DPD gene expressions were measured in 47 primary colorectal cancer tumors and 12 metastatic tumors using FFPE specimens.
|
15222106 |
2004 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
CTD_human |
Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis.
|
19020767 |
2008 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
CTD_human |
In both gastric and colon cancers, thymidylate synthase and orotate phosphoribosyltransferase mRNA expressions were higher (p < 0.0001, p <0.0001 respectively in gastric cancer and P = 0.0002, p < 0.0001 respectively in colon cancer) and dihydropyrimidine dehydrogenase mRNA expressions were lower in cancer cells than in cancerous stroma (P = 0.0136 in gastric cancer and p < 0.0001 in colon cancer).
|
18652704 |
2008 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
CTD_human |
Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.
|
18505590 |
2008 |